Glycans as critical regulators of gut immunity in homeostasis and disease

Cellular Immunology

Volumn 333, Issue , 2018, Pages 9-18

  Dias, Ana M ^a,b   Pereira, Márcia S ^a,b   Padrão, Nuno A ^a,b,c   Alves, Inês ^a,b,c   Marcos Pinto, Ricardo ^b,c,d   Lago, Paula ^d   Pinho, Salomé S ^a,b,c  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c University of Porto   (Portugal)

^d Centro Hospitalar Universitario do Porto   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCAN DERIVATIVE; POLYSACCHARIDE;

ADAPTIVE IMMUNITY; ARTICLE; GLYCOSYLATION; HOMEOSTASIS; HUMAN; IMMUNOPATHOLOGY; IMMUNOREGULATION; INNATE IMMUNITY; INTESTINE MUCOSA; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; ANIMAL; IMMUNOLOGY; INFLAMMATION;

ADAPTIVE IMMUNITY; ANIMALS; HOMEOSTASIS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; POLYSACCHARIDES;

EID: 85050201106     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2018.07.007     Document Type: Article

References (171)

1. Rudd, P.M., Elliott, T., Cresswell, P., Wilson, I.A., Dwek, R.A., Glycosylation and the immune system. Science 291 (2001), 2370–2376.
2. Marth, J.D., Grewal, P.K., Mammalian glycosylation in immunity. Nat. Rev. Immunol. 8 (2008), 874–887.
3. Koropatkin, N.M., Cameron, E.A., Martens, E.C., How glycan metabolism shapes the human gut microbiota. Nat. Rev. Microbiol. 10 (2012), 323–335.
4. Gagneux, P., Aebi, M., Varki, A., Evolution of glycan diversity. Varki, A., Cummings, R.D., Esko, J.D., Stanley, P., Hart, G.W., Aebi, M., Darvill, A.G., Kinoshita, T., Packer, N.H., Prestegard, J.H., Schnaar, R.L., Seeberger, P.H., (eds.) Essentials of glycobiology, 2015, 253–264 Cold Spring Harbor (NY).
5. Kau, A.L., Ahern, P.P., Griffin, N.W., Goodman, A.L., Gordon, J.I., Human nutrition, the gut microbiome and the immune system. Nature 474 (2011), 327–336.
6. Muegge, B.D., Kuczynski, J., Knights, D., Clemente, J.C., Gonzalez, A., Fontana, L., Henrissat, B., Knight, R., Gordon, J.I., Diet drives convergence in gut microbiome functions across mammalian phylogeny and within humans. Science 332 (2011), 970–974.
7. Ravcheev, D.A., Thiele, I., Comparative genomic analysis of the human gut microbiome reveals a broad distribution of metabolic pathways for the degradation of host-synthetized mucin glycans and utilization of mucin-derived monosaccharides. Front. Genet., 8, 2017, 111.
8. Sonnenburg, J.L., Xu, J., Leip, D.D., Chen, C.H., Westover, B.P., Weatherford, J., Buhler, J.D., Gordon, J.I., Glycan foraging in vivo by an intestine-adapted bacterial symbiont. Science 307 (2005), 1955–1959.
9. Tailford, L.E., Crost, E.H., Kavanaugh, D., Juge, N., Mucin glycan foraging in the human gut microbiome. Front. Genet., 6, 2015, 81.
10. Larsson, J.M., Karlsson, H., Sjovall, H., Hansson, G.C., A complex, but uniform O-glycosylation of the human MUC2 mucin from colonic biopsies analyzed by nanoLC/MSn. Glycobiology 19 (2009), 756–766.
11. Larsson, J.M., Karlsson, H., Crespo, J.G., Johansson, M.E., Eklund, L., Sjovall, H., Hansson, G.C., Altered O-glycosylation profile of MUC2 mucin occurs in active ulcerative colitis and is associated with increased inflammation. Inflam. Bowel Dis. 17 (2011), 2299–2307.
12. An, G., Wei, B., Xia, B., McDaniel, J.M., Ju, T., Cummings, R.D., Braun, J., Xia, L., Increased susceptibility to colitis and colorectal tumors in mice lacking core 3-derived O-glycans. J. Experim. Med. 204 (2007), 1417–1429.
13. Ma, X., Dai, Z., Sun, K., Zhang, Y., Chen, J., Yang, Y., Tso, P., Wu, G., Wu, Z., Intestinal epithelial cell endoplasmic reticulum stress and inflammatory bowel disease pathogenesis: an update review. Front. Immunol., 8, 2017, 1271.
14. Kaser, A., Blumberg, R.S., Endoplasmic reticulum stress and intestinal inflammation. Mucosal Immunol. 3 (2010), 11–16.
15. Kaser, A., Martinez-Naves, E., Blumberg, R.S., Endoplasmic reticulum stress: implications for inflammatory bowel disease pathogenesis. Curr. Opin. Gastroenterol. 26 (2010), 318–326.
16. Hasnain, S.Z., Tauro, S., Das, I., Tong, H., Chen, A.C., Jeffery, P.L., McDonald, V., Florin, T.H., McGuckin, M.A., IL-10 promotes production of intestinal mucus by suppressing protein misfolding and endoplasmic reticulum stress in goblet cells. Gastroenterology 144 (2013), 357–368 e359.
17. Julenius, K., NetCGlyc 1.0: prediction of mammalian C-mannosylation sites. Glycobiology 17 (2007), 868–876.
18. Perez-Vilar, J., Randell, S.H., Boucher, R.C., C-Mannosylation of MUC5AC and MUC5B Cys subdomains. Glycobiology 14 (2004), 325–337.
19. Desseyn, J.L., Mucin CYS domains are ancient and highly conserved modules that evolved in concert. Mol. Phylogen. Evol. 52 (2009), 284–292.
20. Boltin, D., Perets, T.T., Vilkin, A., Niv, Y., Mucin function in inflammatory bowel disease: an update. J. Clin. Gastroenterol. 47 (2013), 106–111.
21. Goto, Y., Obata, T., Kunisawa, J., Sato, S., Ivanov, A. II, Lamichhane, N., Takeyama, M., Kamioka, M., Sakamoto, T., Matsuki, H., Setoyama, A., Imaoka, S., Uematsu, S., Akira, S.E., Domino, P., Kulig, B., Becher, J.C., Renauld, C., Sasakawa, Y., Umesaki, Y., Benno, H. Kiyono, Innate lymphoid cells regulate intestinal epithelial cell glycosylation. Science, 345, 2014, 1254009.
22. Artis, D., Spits, H., The biology of innate lymphoid cells. Nature 517 (2015), 293–301.
23. McGovern, D.P., Jones, M.R., Taylor, K.D., Marciante, K., Yan, X., Dubinsky, M., Ippoliti, A., Vasiliauskas, E., Berel, D., Derkowski, C., Dutridge, D., Fleshner, P., Shih, D.Q., Melmed, G., Mengesha, E., King, L., Pressman, S., Haritunians, T., Guo, X., Targan, S.R., Rotter, J.I., International, I.B.D.G.C., Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease. Hum. Mol. Genet. 19 (2010), 3468–3476.
24. Franke, A., McGovern, D.P., Barrett, J.C., Wang, K., Radford-Smith, G.L., Ahmad, T., Lees, C.W., Balschun, T., Lee, J., Roberts, R., Anderson, C.A., Bis, J.C., Bumpstead, S., Ellinghaus, D., Festen, E.M., Georges, M., Green, T., Haritunians, T., Jostins, L., Latiano, A., Mathew, C.G., Montgomery, G.W., Prescott, N.J., Raychaudhuri, S., Rotter, J.I., Schumm, P., Sharma, Y., Simms, L.A., Taylor, K.D., Whiteman, D., Wijmenga, C., Baldassano, R.N., Barclay, M., Bayless, T.M., Brand, S., Buning, C., Cohen, A., Colombel, J.F., Cottone, M., Stronati, L., Denson, T., De Vos, M., D'Inca, R., Dubinsky, M., Edwards, C., Florin, T., Franchimont, D., Gearry, R., Glas, J., Van Gossum, A., Guthery, S.L., Halfvarson, J., Verspaget, H.W., Hugot, J.P., Karban, A., Laukens, D., Lawrance, I., Lemann, M., Levine, A., Libioulle, C., Louis, E., Mowat, C., Newman, W., Panes, J., Phillips, A., Proctor, D.D., Regueiro, M., Russell, R., Rutgeerts, P., Sanderson, J., Sans, M., Seibold, F., Steinhart, A.H., Stokkers, P.C., Torkvist, L., Kullak-Ublick, G., Wilson, D., Walters, T., Targan, S.R., Brant, S.R., Rioux, J.D., D'Amato, M., Weersma, R.K., Kugathasan, S., Griffiths, A.M., Mansfield, J.C., Vermeire, S., Duerr, R.H., Silverberg, M.S., Satsangi, J., Schreiber, S., Cho, J.H., Annese, V., Hakonarson, H., Daly, M.J., Parkes, M., Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat. Genet. 42 (2010), 1118–1125.
25. Kottgen, E., Volk, B., Kluge, F., Gerok, W., Gluten, a lectin with oligomannosyl specificity and the causative agent of gluten-sensitive enteropathy. Biochem. Biophys. Res. Commun. 109 (1982), 168–173.
26. Rouhanifard, S.H., Lopez Aguilar, A., Meng, L., Moremen, K.W., Wu, P., Engineered glycocalyx regulates stem cell proliferation in murine crypt organoids. Cell Chem. Biol. 25 (2018), 439–446 e435.
27. Jiang, H., Lopez-Aguilar, A., Meng, L., Gao, Z., Liu, Y., Tian, X., Yu, G., Ovryn, B., Moremen, K.W., Wu, P., Modulating cell-surface receptor signaling and ion channel functions by in situ glycan editing. Angew. Chem. 57 (2018), 967–971.
28. Rios, D., Wood, M.B., Li, J., Chassaing, B., Gewirtz, A.T., Williams, I.R., Antigen sampling by intestinal M cells is the principal pathway initiating mucosal IgA production to commensal enteric bacteria. Mucosal Immunol. 9 (2016), 907–916.
29. Terahara, K., Nochi, T., Yoshida, M., Takahashi, Y., Goto, Y., Hatai, H., Kurokawa, S., Jang, M.H., Kweon, M.N., Domino, S.E., Hiroi, T., Yuki, Y., Tsunetsugu-Yokota, Y., Kobayashi, K., Kiyono, H., Distinct fucosylation of M cells and epithelial cells by Fut1 and Fut2, respectively, in response to intestinal environmental stress. Biochem. Biophys. Res. Commun. 404 (2011), 822–828.
30. van Kooyk, Y., Rabinovich, G.A., Protein-glycan interactions in the control of innate and adaptive immune responses. Nat. Immunol. 9 (2008), 593–601.
31. Johnson, J.L., Jones, M.B., Ryan, S.O., Cobb, B.A., The regulatory power of glycans and their binding partners in immunity. Trends Immunol. 34 (2013), 290–298.
32. Wolfert, M.A., Boons, G.J., Adaptive immune activation: glycosylation does matter. Nat. Chem. Biol. 9 (2013), 776–784.
33. Feinberg, H., Mitchell, D.A., Drickamer, K., Weis, W.I., Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science 294 (2001), 2163–2166.
34. Svajger, U., Anderluh, M., Jeras, M., Obermajer, N., C-type lectin DC-SIGN: an adhesion, signalling and antigen-uptake molecule that guides dendritic cells in immunity. Cell. Signal. 22 (2010), 1397–1405.
35. Singh, S.K., Stephani, J., Schaefer, M., Kalay, H., Garcia-Vallejo, J.J., den Haan, J., Saeland, E., Sparwasser, T., van Kooyk, Y., Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation. Mol. Immunol. 47 (2009), 164–174.
36. van Kooyk, Y., Geijtenbeek, T.B., DC-SIGN: escape mechanism for pathogens. Nat. Rev. Immunol. 3 (2003), 697–709.
37. van Gisbergen, K.P., Sanchez-Hernandez, M., Geijtenbeek, T.B., van Kooyk, Y., Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN. J. Experim. Med. 201 (2005), 1281–1292.
38. Rabinovich, G.A., Croci, D.O., Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity 36 (2012), 322–335.
39. Perdicchio, M., Ilarregui, J.M., Verstege, M.I., Cornelissen, L.A., Schetters, S.T., Engels, S., Ambrosini, M., Kalay, H., Veninga, H., den Haan, J.M., van Berkel, L.A., Samsom, J.N., Crocker, P.R., Sparwasser, T., Berod, L., Garcia-Vallejo, J.J., van Kooyk, Y., Unger, W.W., Sialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and de novo induction of regulatory T cells. PNAS 113 (2016), 3329–3334.
40. Huang, Y.L., Chassard, C., Hausmann, M., von Itzstein, M., Hennet, T., Sialic acid catabolism drives intestinal inflammation and microbial dysbiosis in mice. Nat. Commun., 6, 2015, 8141.
41. Gophna, U., Sommerfeld, K., Gophna, S., Doolittle, W.F., Veldhuyzen van Zanten, S.J., Differences between tissue-associated intestinal microfloras of patients with Crohn's disease and ulcerative colitis. J. Clin. Microbiol. 44 (2006), 4136–4141.
42. Vanhooren, V., Vandenbroucke, R.E., Dewaele, S., Van Hamme, E., Haigh, J.J., Hochepied, T., Libert, C., Mice overexpressing beta-1,4-Galactosyltransferase I are resistant to TNF-induced inflammation and DSS-induced colitis. PloS One, 8, 2013, e79883.
43. Barreto-Bergter, E., Figueiredo, R.T., Fungal glycans and the innate immune recognition. Front. Cell. Infect. Microbiol., 4, 2014, 145.
44. Byrne, B., Donohoe, G.G., O'Kennedy, R., Sialic acids: carbohydrate moieties that influence the biological and physical properties of biopharmaceutical proteins and living cells. Drug Discov. Today 12 (2007), 319–326.
45. Pozsgay, V., Chu, C., Pannell, L., Wolfe, J., Robbins, J.B., Schneerson, R., Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1. Proceedings of the National Academy of Sciences of the United States of America, 1999, 5194–5197.
46. Cheng, S., Chang, X., Wang, Y., Gao, G.F., Shao, Y., Ma, L., Li, X., Glycosylated enfuvirtide: a long-lasting glycopeptide with potent anti-HIV activity. J. Med. Chem. 58 (2015), 1372–1379.
47. Bednarska, N.G., Wren, B.W., Willcocks, S.J., The importance of the glycosylation of antimicrobial peptides: natural and synthetic approaches. Drug Discov. Today 22 (2017), 919–926.
48. Fox, J.L., Antimicrobial peptides stage a comeback. Nat. Biotechnol. 31 (2013), 379–382.
49. Salzman, N.H., Hung, K., Haribhai, D., Chu, H., Karlsson-Sjoberg, J., Amir, E., Teggatz, P., Barman, M., Hayward, M., Eastwood, D., Stoel, M., Zhou, Y., Sodergren, E., Weinstock, G.M., Bevins, C.L., Williams, C.B., Bos, N.A., Enteric defensins are essential regulators of intestinal microbial ecology. Nat. Immunol. 11 (2010), 76–83.
50. Jain, U., Otley, A.R., Van Limbergen, J., Stadnyk, A.W., The complement system in inflammatory bowel disease. Inflam. Bowel Dis. 20 (2014), 1628–1637.
51. Hartmann, S., Hofsteenge, J., Properdin, the positive regulator of complement, is highly C-mannosylated. J. Biol. Chem. 275 (2000), 28569–28574.
52. Neefjes, J., Jongsma, M.L., Paul, P., Bakke, O., Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat. Rev. Immunol. 11 (2011), 823–836.
53. Smith, K., Boukhaled, G.M., Condotta, S.A., Mazouz, S., Guthmiller, J.J., Vijay, R., Butler, N.S., Bruneau, J., Shoukry, N.H., Krawczyk, C.M., Richer, M.J., Interleukin-10 directly inhibits CD8(+) T Cell function by enhancing N-glycan branching to decrease antigen sensitivity. Immunity 48 (2018), 299–312 e295.
54. Demetriou, M., Granovsky, M., Quaggin, S., Dennis, J.W., Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 409 (2001), 733–739.
55. Dias, A.M., Dourado, J., Lago, P., Cabral, J., Marcos-Pinto, R., Salgueiro, P., Almeida, C.R., Carvalho, S., Fonseca, S., Lima, M., Vilanova, M., Dinis-Ribeiro, M., Reis, C.A., Pinho, S.S., Dysregulation of T cell receptor N-glycosylation: a molecular mechanism involved in ulcerative colitis. Hum. Mol. Genet. 23 (2014), 2416–2427.
56. Dias, A.M., Correia, A., Pereira, M.S., Almeida, C.R., Alves, I., Pinto, V., Catarino, T.A., Mendes, N., Leander, M., Oliva-Teles, M.T., Maia, L., Delerue-Matos, C., Taniguchi, N., Lima, M., Pedroto, I., Marcos-Pinto, R., Lago, P., Reis, C.A., Vilanova, M., Pinho, S.S., Metabolic control of T cell immune response through glycans in inflammatory bowel disease. PNAS 115 (2018), E4651–E4660.
57. Grigorian, A., Lee, S.U., Tian, W., Chen, I.J., Gao, G., Mendelsohn, R., Dennis, J.W., Demetriou, M., Control of T Cell-mediated autoimmunity by metabolite flux to N-glycan biosynthesis. J. Biol. Chem. 282 (2007), 20027–20035.
58. Lau, K.S., Partridge, E.A., Grigorian, A., Silvescu, C.I., Reinhold, V.N., Demetriou, M., Dennis, J.W., Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell 129 (2007), 123–134.
59. Morgan, R., Gao, G., Pawling, J., Dennis, J.W., Demetriou, M., Li, B., N-acetylglucosaminyltransferase V (Mgat5)-mediated N-glycosylation negatively regulates Th1 cytokine production by T cells. J. Immunol. 173 (2004), 7200–7208.
60. Araujo, L., Khim, P., Mkhikian, H., Mortales, C.L., Demetriou, M., Glycolysis and glutaminolysis cooperatively control T cell function by limiting metabolite supply to N-glycosylation. eLife, 6, 2017.
61. Grigorian, A., Araujo, L., Naidu, N.N., Place, D.J., Choudhury, B., Demetriou, M., N-acetylglucosamine inhibits T-helper 1 (Th1)/T-helper 17 (Th17) cell responses and treats experimental autoimmune encephalomyelitis. J. Biol. Chem. 286 (2011), 40133–40141.
62. Chen, I.J., Chen, H.L., Demetriou, M., Lateral compartmentalization of T cell receptor versus CD45 by galectin-N-glycan binding and microfilaments coordinate basal and activation signaling. J. Biol. Chem. 282 (2007), 35361–35372.
63. Stanley, P., Taniguchi, N., Aebi, M., N-Glycans. Varki, A., Cummings, R.D., Esko, J.D., Stanley, P., Hart, G.W., Aebi, M., Darvill, A.G., Kinoshita, T., Packer, N.H., Prestegard, J.H., Schnaar, R.L., Seeberger, P.H., (eds.) Essentials of glycobiology, 2015, 99–111 Cold Spring Harbor (NY).
64. Liu, F.T., Rabinovich, G.A., Galectins: regulators of acute and chronic inflammation. Ann. N. Y. Acad. Sci. 1183 (2010), 158–182.
65. Togayachi, A., Kozono, Y., Ishida, H., Abe, S., Suzuki, N., Tsunoda, Y., Hagiwara, K., Kuno, A., Ohkura, T., Sato, N., Sato, T., Hirabayashi, J., Ikehara, Y., Tachibana, K., Narimatsu, H., Polylactosamine on glycoproteins influences basal levels of lymphocyte and macrophage activation. PNAS 104 (2007), 15829–15834.
66. Mkhikian, H., Mortales, C.L., Zhou, R.W., Khachikyan, K., Wu, G., Haslam, S.M., Kavarian, P., Dell, A., Demetriou, M., Golgi self-correction generates bioequivalent glycans to preserve cellular homeostasis. eLife, 5, 2016.
67. Rabinovich, G.A., Toscano, M.A., Jackson, S.S., Vasta, G.R., Functions of cell surface galectin-glycoprotein lattices. Curr. Opin. Struct. Biol. 17 (2007), 513–520.
68. Liu, F.T., Rabinovich, G.A., Galectins as modulators of tumour progression. Nat. Rev. Cancer 5 (2005), 29–41.
69. Sundblad, V., Morosi, L.G., Geffner, J.R., Rabinovich, G.A., Galectin-1: a jack-of-all-trades in the resolution of acute and chronic inflammation. J. Immunol. 199 (2017), 3721–3730.
70. Toscano, M.A., Bianco, G.A., Ilarregui, J.M., Croci, D.O., Correale, J., Hernandez, J.D., Zwirner, N.W., Poirier, F., Riley, E.M., Baum, L.G., Rabinovich, G.A., Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat. Immunol. 8 (2007), 825–834.
71. Chung, C.D., Patel, V.P., Moran, M., Lewis, L.A., Miceli, M.C., Galectin-1 induces partial TCR zeta-chain phosphorylation and antagonizes processive TCR signal transduction. J. Immunol. 165 (2000), 3722–3729.
72. Chen, H.Y., Fermin, A., Vardhana, S., Weng, I.C., Lo, K.F., Chang, E.Y., Maverakis, E., Yang, R.Y., Hsu, D.K., Dustin, M.L., Liu, F.T., Galectin-3 negatively regulates TCR-mediated CD4+ T-cell activation at the immunological synapse. PNAS 106 (2009), 14496–14501.
73. Paclik, D., Berndt, U., Guzy, C., Dankof, A., Danese, S., Holzloehner, P., Rosewicz, S., Wiedenmann, B., Wittig, B.M., Dignass, A.U., Sturm, A., Galectin-2 induces apoptosis of lamina propria T lymphocytes and ameliorates acute and chronic experimental colitis in mice. J. Mol. Med. 86 (2008), 1395–1406.
74. Tribulatti, M.V., Cattaneo, V., Hellman, U., Mucci, J., Campetella, O., Galectin-8 provides costimulatory and proliferative signals to T lymphocytes. J. Leukocyte Biol. 86 (2009), 371–380.
75. Hokama, A., Mizoguchi, E., Sugimoto, K., Shimomura, Y., Tanaka, Y., Yoshida, M., Rietdijk, S.T., de Jong, Y.P., Snapper, S.B., Terhorst, C., Blumberg, R.S., Mizoguchi, A., Induced reactivity of intestinal CD4(+) T cells with an epithelial cell lectin, galectin-4, contributes to exacerbation of intestinal inflammation. Immunity 20 (2004), 681–693.
76. Mkhikian, H., Grigorian, A., Li, C.F., Chen, H.L., Newton, B., Zhou, R.W., Beeton, C., Torossian, S., Tatarian, G.G., Lee, S.U., Lau, K., Walker, E., Siminovitch, K.A., Chandy, K.G., Yu, Z., Dennis, J.W., Demetriou, M., Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis. Nat. Commun., 2, 2011, 334.
77. Brynedal, B., Wojcik, J., Esposito, F., Debailleul, V., Yaouanq, J., Martinelli-Boneschi, F., Edan, G., Comi, G., Hillert, J., Abderrahim, H., MGAT5 alters the severity of multiple sclerosis. J. Neuroimmunol. 220 (2010), 120–124.
78. Li, C.F., Zhou, R.W., Mkhikian, H., Newton, B.L., Yu, Z., Demetriou, M., Hypomorphic MGAT5 polymorphisms promote multiple sclerosis cooperatively with MGAT1 and interleukin-2 and 7 receptor variants. J. Neuroimmunol. 256 (2013), 71–76.
79. Pereira, M.S., Duraes, C., Catarino, T.A., Cleynen, I., Marcos-Pinto, R., Machado, J.C., Magro, F., Vermeire, S., Lago, P., Pinho, S.S., Genetic variants of MGAT5 gene are associated with ulcerative colitis severity and response to therapy. J. Crohns Colitis 12 (2018), S546–S547.
80. Klasić M., Markulin, D., Vojta, A., Samaržija, I., Biruš I., Dobrinić P., Ventham, N.T., Trbojević-Akmačić I., Šimurina, M., Štambuk, J., Razdorov, G., Kennedy, N.A., Satsangi, J., Dias, A.M., Pinho, S., Annese, V., Latiano, A., D'Inca, R., Lauc, G., Zoldoš V., Promoter methylation of the MGAT3 and BACH2 genes correlates with the composition of the immunoglobulin G glycome in inflammatory bowel disease. Clin. Epigenet., 10, 2018, 75.
81. Fujii, H., Shinzaki, S., Iijima, H., Wakamatsu, K., Iwamoto, C., Sobajima, T., Kuwahara, R., Hiyama, S., Hayashi, Y., Takamatsu, S., Uozumi, N., Kamada, Y., Tsujii, M., Taniguchi, N., Takehara, T., Miyoshi, E., Core fucosylation on T cells, required for activation of T-cell receptor signaling and induction of colitis in mice, is increased in patients with inflammatory bowel disease. Gastroenterology 150 (2016), 1620–1632.
82. Bergstrom, K., Fu, J., Johansson, M.E., Liu, X., Gao, N., Wu, Q., Song, J., McDaniel, J.M., McGee, S., Chen, W., Braun, J., Hansson, G.C., Xia, L., Core 1- and 3-derived O-glycans collectively maintain the colonic mucus barrier and protect against spontaneous colitis in mice. Mucosal Immunol. 10 (2017), 91–103.
83. Wang, Y., Huang, D., Chen, K.Y., Cui, M., Wang, W., Huang, X., Awadellah, A., Li, Q., Friedman, A., Xin, W.W., Di Martino, L., Cominelli, F., Miron, A., Chan, R., Fox, J.G., Xu, Y., Shen, X., Kalady, M.F., Markowitz, S., Maillard, I., Lowe, J.B., Xin, W., Zhou, L., Fucosylation deficiency in mice leads to colitis and adenocarcinoma. Gastroenterology 152 (2017), 193–205 e110.
84. Van der Sluis, M., De Koning, B.A., De Bruijn, A.C., Velcich, A., Meijerink, J.P., Van Goudoever, J.B., Buller, H.A., Dekker, J., Van Seuningen, I., Renes, I.B., Einerhand, A.W., Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 131 (2006), 117–129.
85. Brown, S.J., Miller, A.M., Cowan, P.J., Slavin, J., Connell, W.R., Moore, G.T., Bell, S., Elliott, P.R., Desmond, P.V., d'Apice, A.J., Altered immune system glycosylation causes colitis in alpha1,2-fucosyltransferase transgenic mice. Inflam. Bowel Dis. 10 (2004), 546–556.
86. Macauley, M.S., Kawasaki, N., Peng, W., Wang, S.H., He, Y., Arlian, B.M., McBride, R., Kannagi, R., Khoo, K.H., Paulson, J.C., Unmasking of CD22 Co-receptor on germinal center B-cells occurs by alternative mechanisms in mouse and man. J. Biol. Chem. 290 (2015), 30066–30077.
87. Mak, I.W., Evaniew, N., Ghert, M., Lost in translation: animal models and clinical trials in cancer treatment. Am. J. Transl. Res. 6 (2014), 114–118.
88. Swamy, M., Pathak, S., Grzes, K.M., Damerow, S., Sinclair, L.V., van Aalten, D.M., Cantrell, D.A., Glucose and glutamine fuel protein O-GlcNAcylation to control T cell self-renewal and malignancy. Nat. Immunol. 17 (2016), 712–720.
89. Hart, G.W., Housley, M.P., Slawson, C., Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature 446 (2007), 1017–1022.
90. Hobbs, S.J., Nolz, J.C., Regulation of T cell trafficking by enzymatic synthesis of O-glycans. Front. Immunol., 8, 2017, 600.
91. Smits, H.H., Everts, B., Hartgers, F.C., Yazdanbakhsh, M., Chronic helminth infections protect against allergic diseases by active regulatory processes. Curr. Allergy Asthma Rep. 10 (2010), 3–12.
92. Blum, A.M., Hang, L., Setiawan, T., Urban, J.P. Jr., Stoyanoff, K.M., Leung, J., Weinstock, J.V., Heligmosomoides polygyrus bakeri induces tolerogenic dendritic cells that block colitis and prevent antigen-specific gut T cell responses. J. Immunol. 189 (2012), 2512–2520.
93. Kuijk, L.M., van Die, I., Worms to the rescue: can worm glycans protect from autoimmune diseases?. IUBMB Life 62 (2010), 303–312.
94. Maizels, R.M., Yazdanbakhsh, M., Immune regulation by helminth parasites: cellular and molecular mechanisms. Nat. Rev. Immunol. 3 (2003), 733–744.
95. Matisz, C.E., Faz-Lopez, B., Thomson, E., Al Rajabi, A., Lopes, F., Terrazas, L.I., Wang, A., Sharkey, K.A., McKay, D.M., Suppression of colitis by adoptive transfer of helminth antigen-treated dendritic cells requires interleukin-4 receptor-alpha signaling. Sci. Rep., 7, 2017, 40631.
96. Maizels, R.M., Parasitic helminth infections and the control of human allergic and autoimmune disorders. Clin. Microbiol. Infect. 22 (2016), 481–486.
97. Summers, R.W., Elliott, D.E., Urban, J.F. Jr., Thompson, R.A., Weinstock, J.V., Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 128 (2005), 825–832.
98. Eligio-Garcia, L., Maria del Pilar, C.V., Andres, F.L., Apolinar, C.E., Adrian, C.C., Enedina, J.C., Giardia intestinalis: expression of ubiquitin, glucosamine-6-phosphate and cyst wall protein genes during the encystment process. Experim. Parasitol. 127 (2011), 382–386.
99. Giorgi, M.E., de Lederkremer, R.M., Trans-sialidase and mucins of Trypanosoma cruzi: an important interplay for the parasite. Carbohydr. Res. 346 (2011), 1389–1393.
100. Hasnain, S.Z., McGuckin, M.A., Grencis, R.K., Thornton, D.J., Serine protease(s) secreted by the nematode Trichuris muris degrade the mucus barrier. PLoS Neglect. Trop. Dis., 6, 2012, e1856.
101. van Die, I., Cummings, R.D., Glycan gimmickry by parasitic helminths: a strategy for modulating the host immune response?. Glycobiology 20 (2010), 2–12.
102. Rillahan, C.D., Paulson, J.C., Glycan microarrays for decoding the glycome. Ann. Rev. Biochem. 80 (2011), 797–823.
103. Smith, D.F., Cummings, R.D., Application of microarrays for deciphering the structure and function of the human glycome. Mol. Cell. Proteom: MCP 12 (2013), 902–912.
104. Holst, S., Heijs, B., de Haan, N., van Zeijl, R.J., Briaire-de Bruijn, I.H., van Pelt, G.W., Mehta, A.S., Angel, P.M., Mesker, W.E., Tollenaar, R.A., Drake, R.R., Bovee, J.V., McDonnell, L.A., Wuhrer, M., Linkage-specific in situ sialic acid derivatization for N-glycan mass spectrometry imaging of formalin-fixed paraffin-embedded tissues. Anal. Chem. 88 (2016), 5904–5913.
105. Hinneburg, H., Schirmeister, F., Korac, P., Kolarich, D., N- and O-glycomics from minor amounts of formalin-fixed, paraffin-embedded tissue samples. Meth. Mol. Biol. 1503 (2017), 131–145.
106. Jensen, P.H., Karlsson, N.G., Kolarich, D., Packer, N.H., Structural analysis of N- and O-glycans released from glycoproteins. Nat. Protoc. 7 (2012), 1299–1310.
107. Purohit, S., Li, T., Guan, W., Song, X., Song, J., Tian, Y., Li, L., Sharma, A., Dun, B., Mysona, D., Ghamande, S., Rungruang, B., Cummings, R.D., Wang, P.G., She, J.X., Multiplex glycan bead array for high throughput and high content analyses of glycan binding proteins. Nat. Commun., 9, 2018, 258.
108. Cosnes, J., Gower-Rousseau, C., Seksik, P., Cortot, A., Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 140 (2011), 1785–1794.
109. Lassmann, H., van Horssen, J., Mahad, D., Progressive multiple sclerosis: pathology and pathogenesis. Nat. Rev. Neurol. 8 (2012), 647–656.
110. Bluestone, J.A., Herold, K., Eisenbarth, G., Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464 (2010), 1293–1300.
111. Smolen, J.S., Aletaha, D., McInnes, I.B., Rheumatoid arthritis. Lancet 388 (2016), 2023–2038.
112. Moulton, V.R., Suarez-Fueyo, A., Meidan, E., Li, H., Mizui, M., Tsokos, G.C., Pathogenesis of human systemic lupus erythematosus: a cellular perspective. Trends Mol. Med. 23 (2017), 615–635.
113. D'Haens, G.R., Top-down therapy for IBD: rationale and requisite evidence. Nat. Rev. Gastroenterol. Hepatol. 7 (2010), 86–92.
114. Siebert, S., Porter, D., Paterson, C., Hampson, R., Gaya, D., Latosinska, A., Mischak, H., Schanstra, J., Mullen, W., McInnes, I., Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups. Sci. Rep., 7, 2017, 40473.
115. Mok, C.C., Towards new avenues in the management of lupus glomerulonephritis. Nat. Rev. Rheumatol. 12 (2016), 221–234.
116. Oommen, A.M., Somaiya, N., Vijayan, J., Kumar, S., Venkatachalam, S., Joshi, L., GlycoGAIT: a web database to browse glycogenes and lectins under gastric inflammatory diseases. J. Theoret. Biol. 406 (2016), 93–98.
117. Pereira, M., Carvalho, S., Azevedo, L., Albergaria, A., Lima, J., Reis, C., Pedroto, I., Maia, L., Marcos-Pinto, R., Lago, P., Pinho, S.S., P299 Identification of a prognostic biomarker able to predict ulcerative colitis patients that will not respond to standard therapy. J. Crohn's Colitis, 11, 2017 S229-S229.
118. Quast, I., Peschke, B., Lunemann, J.D., Regulation of antibody effector functions through IgG Fc N-glycosylation. Cell. Mol. Life Sci. CMLS 74 (2017), 837–847.
119. Kaneko, Y., Nimmerjahn, F., Ravetch, J.V., Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313 (2006), 670–673.
120. Shields, R.L., Lai, J., Keck, R., O'Connell, L.Y., Hong, K., Meng, Y.G., Weikert, S.H., Presta, L.G., Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277 (2002), 26733–26740.
121. Franklin, E.C., Structure and function of immunoglobulins. Supplementum Acta Endocrinol 194 (1975), 77–95.
122. Ferrara, C., Grau, S., Jager, C., Sondermann, P., Brunker, P., Waldhauer, I., Hennig, M., Ruf, A., Rufer, A.C., Stihle, M., Umana, P., Benz, J., Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. PNAS 108 (2011), 12669–12674.
123. Malhotra, R., Wormald, M.R., Rudd, P.M., Fischer, P.B., Dwek, R.A., Sim, R.B., Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat. Med. 1 (1995), 237–243.
124. Nimmerjahn, F., Anthony, R.M., Ravetch, J.V., Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. PNAS 104 (2007), 8433–8437.
125. Nakajima, S., Iijima, H., Shinzaki, S., Egawa, S., Inoue, T., Mukai, A., Hayashi, Y., Kondo, J., Akasaka, T., Nishida, T., Kanto, T., Morii, E., Mizushima, T., Miyoshi, E., Tsujii, M., Hayashi, N., Functional analysis of agalactosyl IgG in inflammatory bowel disease patients. Inflam. Bowel Dis. 17 (2011), 927–936.
126. Pagan, J.D., Kitaoka, M., Anthony, R.M., Engineered sialylation of pathogenic antibodies in vivo attenuates autoimmune disease. Cell 172 (2018), 564–577 e513.
127. Trbojevic Akmacic, I., Ventham, N.T., Theodoratou, E., Vuckovic, F., Kennedy, N.A., Kristic, J., Nimmo, E.R., Kalla, R., Drummond, H., Stambuk, J., Dunlop, M.G., Novokmet, M., Aulchenko, Y., Gornik, O., Campbell, H., Pucic Bakovic, M., Satsangi, J., Lauc, G., Consortium, I.-B., Inflammatory bowel disease associates with proinflammatory potential of the immunoglobulin G glycome. Inflam. Bowel Dis. 21 (2015), 1237–1247.
128. Matsumoto, A., Shikata, K., Takeuchi, F., Kojima, N., Mizuochi, T., Autoantibody activity of IgG rheumatoid factor increases with decreasing levels of galactosylation and sialylation. J. Biochem. 128 (2000), 621–628.
129. Gudelj, I., Salo, P.P., Trbojevic-Akmacic, I., Albers, M., Primorac, D., Perola, M., Lauc, G., Low galactosylation of IgG associates with higher risk for future diagnosis of rheumatoid arthritis during 10years of follow-up. Biochim. Biophys. Acta 2018 (1864), 2034–2039.
130. Wuhrer, M., Selman, M.H., McDonnell, L.A., Kumpfel, T., Derfuss, T., Khademi, M., Olsson, T., Hohlfeld, R., Meinl, E., Krumbholz, M., Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid. J. Neuroinflam., 12, 2015, 235.
131. Vuckovic, F., Kristic, J., Gudelj, I., Teruel, M., Keser, T., Pezer, M., Pucic-Bakovic, M., Stambuk, J., Trbojevic-Akmacic, I., Barrios, C., Pavic, T., Menni, C., Wang, Y., Zhou, Y., Cui, L., Song, H., Zeng, Q., Guo, X., Pons-Estel, B.A., McKeigue, P., Leslie Patrick, A., Gornik, O., Spector, T.D., Harjacek, M., Alarcon-Riquelme, M., Molokhia, M., Wang, W., Lauc, G., Association of systemic lupus erythematosus with decreased immunosuppressive potential of the IgG glycome. Arthrit. Rheumatol. 67 (2015), 2978–2989.
132. Gornik, I., Maravic, G., Dumic, J., Flogel, M., Lauc, G., Fucosylation of IgG heavy chains is increased in rheumatoid arthritis. Clin. Biochem. 32 (1999), 605–608.
133. Miyahara, K., Nouso, K., Saito, S., Hiraoka, S., Harada, K., Takahashi, S., Morimoto, Y., Kobayashi, S., Ikeda, F., Miyake, Y., Shiraha, H., Takaki, A., Okada, H., Amano, M., Hirose, K., Nishimura, S., Yamamoto, K., Serum glycan markers for evaluation of disease activity and prediction of clinical course in patients with ulcerative colitis. PloS One, 8, 2013, e74861.
134. Simurina, M., de Haan, N., Vuckovic, F., Kennedy, N.A., Stambuk, J., Falck, D., Trbojevic-Akmacic, I., Clerc, F., Razdorov, G., Khon, A., Latiano, A., D'Inca, R., Danese, S., Targan, S., Landers, C., Dubinsky, M., Inflammatory Bowel Disease Biomarkers, C., McGovern, D.P.B., Annese, V., Wuhrer, M., Lauc, G., glycosylation of immunoglobulin G associates with clinical features of inflammatory bowel diseases. Gastroenterology 154 (2018), 1320–1333 e1310.
135. Rook, G.A., Steele, J., Brealey, R., Whyte, A., Isenberg, D., Sumar, N., Nelson, J.L., Bodman, K.B., Young, A., Roitt, I.M., et al. Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy. J. Autoimmun. 4 (1991), 779–794.
136. Parekh, R.B., Roitt, I.M., Isenberg, D.A., Dwek, R.A., Ansell, B.M., Rademacher, T.W., Galactosylation of IgG associated oligosaccharides: reduction in patients with adult and juvenile onset rheumatoid arthritis and relation to disease activity. Lancet 1 (1988), 966–969.
137. Ercan, A., Cui, J., Chatterton, D.E., Deane, K.D., Hazen, M.M., Brintnell, W., O'Donnell, C.I., Derber, L.A., Weinblatt, M.E., Shadick, N.A., Bell, D.A., Cairns, E., Solomon, D.H., Holers, V.M., Rudd, P.M., Lee, D.M., Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthrit. Rheum. 62 (2010), 2239–2248.
138. Gomollon, F., Biosimilars: are they bioequivalent?. Digest. Dis. 32:Suppl 1 (2014), 82–87.
139. Sha, S., Agarabi, C., Brorson, K., Lee, D.Y., Yoon, S., N-glycosylation design and control of therapeutic monoclonal antibodies. Trends Biotechnol. 34 (2016), 835–846.
140. Sola, R.J., Griebenow, K., Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy. BioDrugs Clin. Immunother. Biopharmaceut. Gene Ther. 24 (2010), 9–21.
141. Plomp, R., Bondt, A., de Haan, N., Rombouts, Y., Wuhrer, M., Recent advances in clinical glycoproteomics of immunoglobulins (Igs). Mol. Cell. Proteom. MCP 15 (2016), 2217–2228.
142. Schwab, I., Nimmerjahn, F., Intravenous immunoglobulin therapy: how does IgG modulate the immune system?. Nat. Rev. Immunol. 13 (2013), 176–189.
143. Nimmerjahn, F., Ravetch, J.V., Anti-inflammatory actions of intravenous immunoglobulin. Ann. Rev. Immunol. 26 (2008), 513–533.
144. Imbach, P., Barandun, S., d'Apuzzo, V., Baumgartner, C., Hirt, A., Morell, A., Rossi, E., Schoni, M., Vest, M., Wagner, H.P., High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1 (1981), 1228–1231.
145. Anthony, R.M., Wermeling, F., Karlsson, M.C., Ravetch, J.V., Identification of a receptor required for the anti-inflammatory activity of IVIG. PNAS 105 (2008), 19571–19578.
146. Anthony, R.M., Kobayashi, T., Wermeling, F., Ravetch, J.V., Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 475 (2011), 110–113.
147. Fiebiger, B.M., Maamary, J., Pincetic, A., Ravetch, J.V., Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs. Proc. Natl. Acad. Sci. U.S.A. 112 (2015), E2385–E2394.
148. Khoruts, A., Sadowsky, M.J., Understanding the mechanisms of faecal microbiota transplantation. Nat. Rev. Gastroenterol. Hepatol. 13 (2016), 508–516.
149. Paramsothy, S., Paramsothy, R., Rubin, D.T., Kamm, M.A., Kaakoush, N.O., Mitchell, H.M., Castano-Rodriguez, N., Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysis. J. Crohn's Colitis 11 (2017), 1180–1199.
150. Kump, P.K., Grochenig, H.P., Lackner, S., Trajanoski, S., Reicht, G., Hoffmann, K.M., Deutschmann, A., Wenzl, H.H., Petritsch, W., Krejs, G.J., Gorkiewicz, G., Hogenauer, C., Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflam. Bowel Dis. 19 (2013), 2155–2165.
151. Damman, C.J., Miller, S.I., Surawicz, C.M., Zisman, T.L., The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation?. Am. J. Gastroenterol. 107 (2012), 1452–1459.
152. Vermeire, S., Joossens, M., Verbeke, K., Wang, J., Machiels, K., Sabino, J., Ferrante, M., Van Assche, G., Rutgeerts, P., Raes, J., Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease. J. Crohn's Colitis 10 (2016), 387–394.
153. Lauc, G., Huffman, J.E., Pucic, M., Zgaga, L., Adamczyk, B., Muzinic, A., Novokmet, M., Polasek, O., Gornik, O., Kristic, J., Keser, T., Vitart, V., Scheijen, B., Uh, H.W., Molokhia, M., Patrick, A.L., McKeigue, P., Kolcic, I., Lukic, I.K., Swann, O., van Leeuwen, F.N., Ruhaak, L.R., Houwing-Duistermaat, J.J., Slagboom, P.E., Beekman, M., de Craen, A.J., Deelder, A.M., Zeng, Q., Wang, W., Hastie, N.D., Gyllensten, U., Wilson, J.F., Wuhrer, M., Wright, A.F., Rudd, P.M., Hayward, C., Aulchenko, Y., Campbell, H., Rudan, I., Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. PLoS Genet., 9, 2013, e1003225.
154. Suzuki, K., Yamada, T., Yamazaki, K., Hirota, M., Ishihara, N., Sakamoto, M., Takahashi, D., Iijima, H., Hase, K., Intestinal epithelial cell-specific deletion of alpha-mannosidase II ameliorates experimental colitis. Cell Struct. Funct. 43 (2018), 25–39.
155. Tong, M., McHardy, I., Ruegger, P., Goudarzi, M., Kashyap, P.C., Haritunians, T., Li, X., Graeber, T.G., Schwager, E., Huttenhower, C., Fornace, A.J. Jr., Sonnenburg, J.L., McGovern, D.P., Borneman, J., Braun, J., Reprograming of gut microbiome energy metabolism by the FUT2 Crohn's disease risk polymorphism. ISME J. 8 (2014), 2193–2206.
156. Rausch, P., Rehman, A., Kunzel, S., Hasler, R., Ott, S.J., Schreiber, S., Rosenstiel, P., Franke, A., Baines, J.F., Colonic mucosa-associated microbiota is influenced by an interaction of Crohn disease and FUT2 (Secretor) genotype. PNAS 108 (2011), 19030–19035.
157. Hu, D., Zhang, D., Zheng, S., Guo, M., Lin, X., Jiang, Y., Association of ulcerative colitis with FUT2 and FUT3 polymorphisms in patients from Southeast China. PloS One, 11, 2016, e0146557.
158. Lakatos, P.L., Papp, M., Rieder, F., Serologic antiglycan antibodies in inflammatory bowel disease. Am. J. Gastroenterol. 106 (2011), 406–412.
159. Masoodi, I., Kochhar, R., Dutta, U., Vaishnavi, C., Prasad, K.K., Vaiphei, K., Kaur, S., Singh, K., Fecal lactoferrin, myeloperoxidase and serum C-reactive are effective biomarkers in the assessment of disease activity and severity in patients with idiopathic ulcerative colitis. J. Gastroenterol. Hepatol. 24 (2009), 1768–1774.
160. Siqueiros-Cendon, T., Arevalo-Gallegos, S., Iglesias-Figueroa, B.F., Garcia-Montoya, I.A., Salazar-Martinez, J., Rascon-Cruz, Q., Immunomodulatory effects of lactoferrin. Acta Pharmacol. Sin. 35 (2014), 557–566.
161. Shinzaki, S., Kuroki, E., Iijima, H., Tatsunaka, N., Ishii, M., Fujii, H., Kamada, Y., Kobayashi, T., Shibukawa, N., Inoue, T., Tsujii, M., Takeishi, S., Mizushima, T., Ogata, A., Naka, T., Plevy, S.E., Takehara, T., Miyoshi, E., Lectin-based immunoassay for aberrant IgG glycosylation as the biomarker for Crohn's disease. Inflam. Bowel Dis. 19 (2013), 321–331.
162. Cremata, J.A., Sorell, L., Montesino, R., Garcia, R., Mata, M., Cabrera, G., Galvan, J.A., Garcia, G., Valdes, R., Garrote, J.A., Hypogalactosylation of serum IgG in patients with coeliac disease. Clin. Experim. Immunol. 133 (2003), 422–429.
163. Lindfors, K., Suzuki, H., Novak, J., Collin, P., Saavalainen, P., Koskinen, L.L., Maki, M., Kaukinen, K., Galactosylation of serum IgA1 O-glycans in celiac disease. J. Clin. Immunol. 31 (2011), 74–79.
164. Urushihara, M., Kagami, S., Yasutomo, K., Ito, M., Kondo, S., Kitamura, A., Malm, D., Klenow, H., Nilssen, O., Kuroda, Y., Sisters with alpha-mannosidosis and systemic lupus erythematosus. Eur. J. Pediat. 163 (2004), 192–195.
165. Chui, D., Sellakumar, G., Green, R., Sutton-Smith, M., McQuistan, T., Marek, K., Morris, H., Dell, A., Marth, J., Genetic remodeling of protein glycosylation in vivo induces autoimmune disease. PNAS 98 (2001), 1142–1147.
166. Liu, S.D., Lee, S., La Cava, A., Motran, C.C., Hahn, B.H., Miceli, M.C., Galectin-1-induced down-regulation of T lymphocyte activation protects (NZB x NZW) F1 mice from lupus-like disease. Lupus 20 (2011), 473–484.
167. Panda, S.K., Facchinetti, V., Voynova, E., Hanabuchi, S., Karnell, J.L., Hanna, R.N., Kolbeck, R., Sanjuan, M.A., Ettinger, R., Liu, Y.J., Galectin-9 inhibits TLR7-mediated autoimmunity in murine lupus models. J. Clin. Investig. 128 (2018), 1873–1887.
168. Moritoki, M., Kadowaki, T., Niki, T., Nakano, D., Soma, G., Mori, H., Kobara, H., Masaki, T., Kohno, M., Hirashima, M., Galectin-9 ameliorates clinical severity of MRL/lpr lupus-prone mice by inducing plasma cell apoptosis independently of Tim-3. PloS One, 8, 2013, e60807.
169. Oomizu, S., Arikawa, T., Niki, T., Kadowaki, T., Ueno, M., Nishi, N., Yamauchi, A., Hirashima, M., Galectin-9 suppresses Th17 cell development in an IL-2-dependent but Tim-3-independent manner. Clin. Immunol. 143 (2012), 51–58.
170. Kanzaki, M., Wada, J., Sugiyama, K., Nakatsuka, A., Teshigawara, S., Murakami, K., Inoue, K., Terami, T., Katayama, A., Eguchi, J., Akiba, H., Yagita, H., Makino, H., Galectin-9 and T cell immunoglobulin mucin-3 pathway is a therapeutic target for type 1 diabetes. Endocrinology 153 (2012), 612–620.
171. Sawin, E.A., De Wolfe, T.J., Aktas, B., Stroup, B.M., Murali, S.G., Steele, J.L., Ney, D.M., Glycomacropeptide is a prebiotic that reduces Desulfovibrio bacteria, increases cecal short-chain fatty acids, and is anti-inflammatory in mice, American journal of physiology. Gastrointest. Liver Physiol. 309 (2015), G590–G601.